The process of clinical trials underwent a dramatic transformation amid the COVID-19 pandemic, according to Heidi D. Finnes, PharmD, BCOP, FHOPA, RPh, Senior Manager, Pharmacy Cancer Research, Mayo Clinic, Rochester, MN.
Breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, appears to be an effective alternative to surgery for women aged >60 years with low-risk, early-stage breast cancer, according to findings from the ICE3 trial.
The addition of the PI3K inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial.
The July issue of The Oncology Pharmacist (TOP) contains important information for today’s oncology pharmacist, including highlights from several presentations made during the 2021 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference and other key oncology meetings.
Neutropenia is characterized by low levels of neutrophils, the white blood cells that fight infections. In general, the condition is defined as an absolute neutrophil count (ANC) <1500/μL. There are several factors that can contribute to the development of neutropenia, including idiopathic and congenital etiologies, as well as some cancers, such as leukemia, myeloma, and lymphoma. However, one of the most common causes of neutropenia is the use of chemotherapy. The following provides a brief look at some of the key statistics regarding this condition.
For more than 40 years, healthcare professionals, public health advocates, and healthcare strategists have been discussing health inequities that consistently and disproportionately affect groups of color in the United States.